October 8th 2024
The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.
September 25th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 5th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
Read More
BI 1810631 Shows Early Antitumor Activity in NSCLC
December 4th 2022Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.
Read More
Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC
December 1st 2022"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.
Read More
Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC
November 26th 2022Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.
Read More
Choosing Early-Line Therapy for NSCLC With an EGFR Exon 20 Insertion
November 16th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Read More
Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion
October 19th 2022During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.
Read More
FDA Fast Tracks BBP-398 and Sotorasib Combination for Adults With Advanced KRAS G12C+ NSCLC
October 12th 2022Considering the potential to fill a treatment gap in the KRAS G12C-mutant non–small cell lung cancer population, the FDA has granted a fast track designation to the combination of BBP-398 and sotorasib.
Read More
FDA’s ODAC Votes That Benefits Do Not Outweigh Risks for Poziotinib in HER Exon 20 Ins+ NSCLC
September 22nd 2022Based on the efficacy, toxicity, dose-optimization, and lack of confirmatory data for poziotinib in HER2 exon 20 insertion-positive non–small cell lung cancer, ODAC has voted that the drug has an unfavorable risk/benefit profile.
Read More
Study of DZD9008 Meets Primary End Point of ORR in EGFR Exon20Ins-Positive NSCLC
September 14th 2022Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations.
Read More
Liquid Biopsy HIC Proteomic Testing May Aid in NSCLC Treatment Decision-Making
September 2nd 2022In an interview with Targeted Oncology, David Oubre, MD discussed the use of liquid biopsy to identify prognostic and predictive biomarkers in patients with non–small cell lung cancer. He also explained the results and implications of the INSIGHT study.
Read More
Improvements in Medicaid Will Lead to Better Patient Outcomes in NSCLC
August 23rd 2022Cary Gross, MD, discusses the key takeaways from his retrospective research examining patients with advanced non–small cell lung cancer and its association with Medicaid insurance, rates of biomarker testing, and patient outcomes.
Watch
NGS Testing May Be Better Than Single-Gene Testing for Identifying Mutations in NSCLC
August 18th 2022In an interview with Targeted Oncology, Brandon Sheffield, MD, discussed relevant biomarkers for testing in patients with non–small cell lung cancer, and the cost-effectiveness of single-gene test vs next-generation sequencing.
Read More
Optimal Precision Medicine Practices Not Commonly Performed for Medicaid Beneficiaries With NSCLC
August 17th 2022In an interview with Targeted Oncology, Cary Gross, MD, discussed retrospective research that revealed testing and treatment disparities among Medicaid beneficiaries with advanced non–small cell lung cancer, and the steps needed to improve outcomes for the patient population.
Read More
FDA Grants Regular Approval to Capmatinib for Patients With METex14-Positive NSCLC
August 11th 2022An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.
Read More
Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLC
August 9th 2022The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.
Read More
Sitravatinib Plus Tislelizumab Elicits Antitumor Activity in PD-L1+ Advanced NSCLC
August 7th 2022Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.
Read More
Promising Safety With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLC
August 7th 2022Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.
Read More